MicroRNA-451: Epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma

Oncotarget

Volumn 6, Issue 21, 2015, Pages 18613-18630

  Huang, Jia Yuan ^a   Zhang, Kai ^a   Chen, Dong Qin ^a   Chen, Jing ^a   Feng, Bing ^a   Song, Haizhu ^a   Chen, Yitian ^a   Zhu, Ziman ^b   Lu, Lei ^c   De, Wei ^d   Wang, Rui ^a   Chen, Long Bang ^a  

^a NANJING UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c The 81th Hospital of PLA   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

c Myc; Epithelial mesenchymal transition; Hepatocellular carcinoma; Invasion; miR 451

Indexed keywords

GELATINASE A; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; MICRORNA; MICRORNA 451; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; MIRN451 MICRORNA, HUMAN; MYC PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; CELL LINE; CELL MOTION; CELL PROLIFERATION; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84938787433     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4317     Document Type: Article

References (55)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 3210-3216.
3. Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, et al. Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol 2014; 20: 14381-14392.
4. Meng F, Wu G. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev 2012; 31: 455-467.
5. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010; 101: 293-299.
6. Ogunwobi OO, Liu C. Therapeutic and prognostic importance of epithelial-mesenchymal transition in liver cancers: insights from experimental models. Crit Rev Oncol Hematol 2012; 83: 319-328.
7. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 2009; 5: 1169-1179.
8. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome 2006; 17: 189-202.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
10. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009; 28: 369-378.
11. Cui SY, Wang R, Chen LB. MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J Cell Mol Med 2013; 17: 1207-1217.
12. Zhao L, Lu X, Cao Y. MicroRNA and signal transduction pathways in tumor radiation response. Cell Signal 2013; 25: 1625-1634.
13. Rong M, Chen G, Dang Y. Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer 2013; 13: 21.
14. Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology 2011; 54: 2064-2075.
15. Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2014; 33: 2557-2567.
16. Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem 2013; 383: 49-58.
17. Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK). Oncogene 2012; 31: 3607-3620.
18. Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013; 58: 158-170.
19. Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX, et al. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med 2013; 210: 789-803.
20. Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011; 30: 2644-2658.
21. Wang R, Chen DQ, Huang JY, Zhang K, Feng B, Pan BZ, et al. Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling. Oncotarget 2014; 5: 6113-6129.
22. Chen D, Huang J, Zhang K, Pan B, Chen J, De W, et al. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer 2014 Oct 10. [Epub ahead of print]
23. Li HP, Zeng XC, Zhang B, Long JT, Zhou B, Tan GS, et al. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-ß. Carcinogenesis 2013; 34: 2443-2451.
24. Lv G, Hu Z, Tie Y, Du J, Fu H, Gao X, et al. MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration. Oncol Rep 2014; 32: 1021-1028.
25. Cho KB, Cho MK, Lee WY, Kang KW. Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett 2010; 293: 230-239.
26. Han G, Wang Y, Bi W. C-Myc overexpression promotes osteosarcoma cell invasion via activation of MEK-ERK pathway. Oncol Res 2012; 20: 149-156.
27. Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY, et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 2007; 67: 4564-4571.
28. Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T, et al. Glycogen synthase kinase-3 beta regulates Snail and ß-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer 2013; 49: 2734-2746.
29. McManus MT. MicroRNAs and cancer. Semin Cancer Biol 2003; 13: 253-258.
30. Pan X, Wang R, Wang ZX. The potential role of miR-451 in cancer diagnosis, prognosis, and therapy. Mol Cancer Ther 2013; 12: 1153-1162.
31. Liu X, Zhang X, Xiang J, Lv Y, Shi J. miR-451: potential role as tumor suppressor of human hepatoma cell growth and invasion. Int J Oncol 2014; 45: 739-745.
32. Li HY, Zhang Y, Cai JH, Bian HL. MicroRNA-451 inhibits growth of human colorectal carcinoma cells via downregulation of Pi3k/Akt pathway. Asian Pac J Cancer Prev 2013; 14: 3631-3634.
33. Tian Y, Nan Y, Han L, Zhang A, Wang G, Jia Z, et al. MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. Int J Oncol 2012; 40: 1105-1112.
34. Liu D, Liu C, Wang X, Ingvarsson S, Chen H. MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression. Cancer Epidemiol 2014; 38: 85-92.
35. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M, et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell 2010; 37: 620-632.
36. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S. microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle 2010; 9: 2742-2748.
37. Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of nonsmall cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011; 30: 20.
38. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-2159.
39. Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012; 31: 39-47.
40. Lopotová T, Zácková M, Klamová H, Moravcová J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk Res 2011; 35: 974-977.
41. Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 643-650.
42. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, et al. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res 2011; 71: 7670-7682.
43. Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. The Journal of cell biology 2011; 195: 417-433.
44. Zhang JP, Zeng C, Xu L, Gong J, Fang JH, Zhuang SM. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene 2014; 33: 4069-4076.
45. Zhou Y, Li Y, Ye J, Jiang R, Yan H, Yang X, et al. MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition. Liver Int 2013; 33: 1271-1280.
46. Yau WL, Lam CS, Ng L, Chow AK, Chan ST, Chan JY, et al. Over-expression of miR-106b promotes cell migration and metastasis in hepatocellular carcinoma by activating epithelial-mesenchymal transition process. PLoS One 2013; 8: e57882.
47. Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013; 58: 629-641.
48. Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene 2010; 29: 2161-2164.
49. Dai MS, Lu H. Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem 2008; 105: 670-677.
50. Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol 2010; 2: 16-20.
51. Li X, Sanda T, Look AT, Novina CD, von Boehmer H. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J Exp Med 2011; 208: 663-675.
52. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
53. Fenger JM, Bear MD, Volinia S, Lin TY, Harrington BK, London CA, et al. Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis. BMC Cancer 2014; 14: 84.
54. Morimoto AM1, Tan N, West K, McArthur G, Toner GC, Manning WC, Smolich BD, et al. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 2004; 23: 1618-1626.
55. Cui SY, Huang JY, Chen YT, Song HZ, Feng B, Huang GC, et al. Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma. Mol Cancer Res 2013; 11: 699-713.